Special Feature

User Panel

My Panel

My Panel

Bookmark Science Articles

Recent News
Bookmark / Share This Science Site

[Anti-tuberculosis chemotherapy]

[Anti-tuberculosis chemotherapy] Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

  • Abstract Text of This Paper
  • Journal Published
  • MeSH Keywords of This Abstract
  • Chemicals and Substances Used in this Paper
  • Grants and Granting Agency of this Research
  • Database Accession Numbers Used in this Paper
  • Related Papers
  • Related Research Tags
  • Rate this Research Paper
  • [Anti-tuberculosis chemotherapy] Abstract Text:

    masako wadaMasako Wada,masako wadaMasako Wada,

    The era of the modem chemotherapy in the treatment of tuberculosis has started by the discovery of streptomycin in 1943. Soon after the introduction of SM, it became evident that drug-resistance against streptomycin (SM) quickly emerged when used singly, and the combination therapy with para-aminosalicylate (PAS) and isoniazid (INH), both of which were developed a little later, had been the standard regimens for the treatment of tuberculosis. But, long-term therapy, more than a year, sometimes of two or three years, was required to get recovered from tuberculosis by three-drug combination therapy of SM-PAS-INH. Introduction of rifampicin (RFP) in 1966 and re-evaluation of pyrazinamide (PZA) in early 1970's have brought a revolutionary change in the concept of tuberculosis chemotherapy, and very potent six-month regimen, consisting of two-month initial intensive phase (INH-RFP-PZA and EB or SM) and four-month maintenance phase (INH-RFP) has been established as the global standard regimen. Tuberculosis chemotherapy has liberated tuberculosis patients from lengthy stay in sanatoria or hospitals. Now, tuberculosis patients could be and should be treated by the intensive short-course chemotherapy under ambulatory settings. One of the most serious obstacles of ambulatory treatment is the incompliance of the patients to the prescribed regimen. Obvious outcome of such incompliance is the treatment failure at the level of individual patients and also the prevalence of multidrug-resistant- (MDR-) and extensively drug-resistant- (XDR-) tuberculosis all over the world. MDR-and XDR-tuberculosis are already threatening tuberculosis control policy in some countries and districts in the world. Early diagnosis of infectious patients and successful treatment of newly diagnosed patients under DOTS are the most recommendable strategies to prevent the emergency of MDR-and XDR-tuberculosis worldwide. In Japan, the policy of tuberculosis treatment has been more or less diverged from the global standards, namely, higher rate of hospitalization, longer hospitalization periods, and longer treatment. One of the most important reasons for such cost-effectively inefficient practices is the lack of reliable and practical DOT system for ambulatory treatment. Recently, we successfully completed a trial to implement a DOT system in which the city-pharmacists served as the observer. We believe that this system is well acceptable for both city-pharmacies and tuberculosis patients, and expect to be adapted through the whole country. New anti-tuberculosis drugs which enable the intermittent therapy of much shorter duration are eagerly expected.

    [Anti-tuberculosis chemotherapy] Publishing Authors By Initials

    m wadaM Wada,m wadaM Wada,

    For similar abstracts research abstracts see: abstracts research

    PUBMED ID PMID:

    MEDLINE DATE:

    [Anti-tuberculosis chemotherapy] Journal Published:

    PUBLICATION TYPE: Journal Article

    Journal: Kekkaku : [Tuberculosis]

    VOLUME: 82

    Page Numbers: 771-81

    Journal Abbreviation: Kekkaku

    ISSN: 0022-9776

    DAY: 16

    MONTH: Oct

    YEAR: 2007

    [Anti-tuberculosis chemotherapy] Information

    Number of References:

    LANGUAGE: jpn

    NlmUniqueID: 422132

    [Anti-tuberculosis chemotherapy] Keywords Mesh Terms:

    KEYWORDS:

    MESH TERMS:

    Chemical & Substance for Abstract: [Anti-tuberculosis chemotherapy] Information

    Substance Name:

    Registry Number:

    Grant and Affiliation Information for [Anti-tuberculosis chemotherapy]

    AFFILIATION: Research Institute of Tuberculosis, Japan Anti-Tuberculosis Association, Kiyose-shi, Tokyo. wada@jata.or.jp

    Country: Japan

    Japan Research PublicationJapan Research Publication

    AGENCY:

    GRANT:

    ACRONYM:

    MEDLINETA: Kekkaku

    REFSOURCE:

    DATABASENAME:

    ACCESSION NUMBER:

    Number Hits: 0

    Anti-tuberculosis chemotherapy Related Publications

     

    Molecular Station USER Menu

    Welcome to Molecular Station!

    You have to register before you can post on our forums or use our advanced features. Register Now! Its Free and Fast!

    Already registered? Login now below.

    User Name:

    Password:

    Already registered and Forgot your password? Click below to recover it.

    Recover Lost Password

    Join now - it's fast and free!

    Molecular Station is THE largest network of researchers, scientists and science lovers anywhere!

    Research Terms of Usage and Disclaimer
    Home
    Features

    Protocols

    DNA Forum

    Science Forum

    DNA Forum
    Biology Forum

    Science News


    [CaRP] XML error: Invalid document end at line 2

    For more click here:Science News